

Recipharm launches Recipharm Analytical Solutions™ as its stand-alone offering for analytical chemistry

Recipharm, the contract development and manufacturing organisation (CDMO), has launched Recipharm Analytical Solutions™, a stand-alone service to support pharmaceutical companies with their Quality Control (QC) and analytical requirements.

Recipharm Analytical Solutions™, which launches at CPhI Worldwide, November 5 – 7, Frankfurt, Germany, offers analytical services including method development, method validation, and stability program design and implementation.

The newly launched solution leverages Recipharm's vast experience and the scale of its laboratories to offer additional capacity to QC and analytical laboratories facing resource challenges, while also aiming to reduce timelines and costs.

The service launches as Recipharm opens a brand-new analytical chemistry laboratory and additional stability walk-in chambers at its facility in Bengaluru, India. This laboratory in Bengaluru, which is the 9th addition to Recipharm's overall global analytical solutions offering and was commissioned in response to customer demand and became operational in October.

Commenting on the announcement, Dr. Ramesh Jagadeesan, Director of Analytical Development at Recipharm said: "Reducing time to market is a key consideration throughout every stage of drug development. By taking an innovative approach to analytical chemistry and using our expertise and capacity, we can improve efficiencies and reduce vital timelines for our customers. For example, worldwide, we are more than 160 analytical scientists that can perform analyses in parallel, share experience of all sorts of molecules and formulations and have the time to focus on finding solutions to customer challenges."

"Many customers place their full stability programs with us, thus offloading their own QC labs, giving them capacity to focus on core activities."

"Our understanding of the entire drug development and manufacturing process delivers many benefits, including the ability to develop robust methods made for the stream-lined conditions within QC labs. We are used to working closely with formulation development teams with regulatory implications in mind. We also understand the logistics involved in the scale-up and tech transfer of a drug product, meaning transferring analytical methods should never be an issue."

For pharmaceutical companies located outside the EU who are looking to export into the market, Recipharm offers an analytical service as well as a quality release service, also known as EU gateway release.

Recipharm Analytical Solutions™ includes specialist expertise in analytical techniques including in vitro permeation testing/in vitro release testing methods (IVPT/IVRT), performance testing of inhalation products and extractables and leachables (E&L). Customers can access the service via various contracts, ranging from individual projects to fully dedicated laboratories.

For more information, visit: <https://www.recipharm.com/solutions/recipharm-analytical-solutions>



Contact information

Maria Lundberg, Vice President Analytical Development, maria.lundberg@recipharm.com, + 46 8 6025 253

For media enquiries, please contact Kate Hindhaugh at [ramarketingpr.com](mailto:kate@ramarketingpr.com): kate@ramarketingpr.com, + 44 (0)191 222 1242, ramarketingpr.com, Twitter: [@ramarketingpr](https://twitter.com/ramarketingpr), Facebook: [/ramarketingpr](https://facebook.com/ramarketingpr), LinkedIn: [/ramarketing](https://linkedin.com/company/ramarketingpr)

About Recipharm

Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing around 6,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm's turnover is approximately SEK 6.4 billion and the company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.

For more information on Recipharm and our services, please visit www.recipharm.com